Bailey Perrin Bailey aggressively represents individuals throughout the state of Texas and the entire United States. The firm has earned the reputation as a leader civil litigation by working tirelessly to get our clients the best results possible.
Bailey Perrin Bailey is a leader in drug litigation. Having participated in numerous settlements and lawsuits to date, we have amassed tremendous experience and resources in many types of pharmaceutical litigation.
Because of our dedication to excellence and a history of getting significant results for our clients, many of our cases come to us through referrals from other clients, colleagues and law firms.
Unparalleled Commitment to Our ClientsLeaders in Atypical Antipsychotic Litigation Atypical antipsychotic drugs, including Risperdal, Seroquel and Zyprexa, have been linked to an increased risk of obesity, diabetes and other blood suger disorders. The FDA has required the manufacturers of these drugs to update the labels to warn about these risks. Bailey Perrin Bailey LLP successfully negotiated a settlement on behalf of hundreds of Zyprexa patients. Currently, the firm is representing thousands of clients who suffer from Seroquel and Risperdal side effects. Click below for more information on Seroquel, Risperdal & Zyprexa. Leaders in Seroquel Litigation Seroquel is used to treat schizophrenia and bipolar mania
that has been linked to increased risk of diabetes, hyperglycemia,
and weight gain. A study by the NIH showed that 12% of Seroquel
patients experienced significant weight gain. In April 2004,
the FDA and AstraZeneca notified healthcare professionals
of revision to the WARNINGS section of labeling, describing
the increased risk of hyperglycemia and diabetes in patients
taking Seroquel. Leaders in Risperdal Litigation Risperdal is a atypical antipsychotic, manufactured by Janssen
Pharmaceutica, that is used to treat schizophrenia and bipolar
mania. The drug has been linked to increased risk of diabetes,
hyperglycemia, and weight gain. As a result, the FDA the
drug's manufacturer revised the WARNINGS section of labeling,
describing the increased risk of hyperglycemia and diabetes
in patients taking Risperdal. Leaders in Zyprexa Litigation *Bailey Perrin Bailey LLP is no longer accepting Zyprexa
cases. Zyprexa has been linked to weight gain, diabetes, glucose
problems, increased cholesterol, and increased triglycerides.
In studies, patients taking Zyprexa gained an average of two pounds per
month. 31% of Zyprexa recipients found the weight gain or
metabolic effects so distressing that they chose to stop
treatment. |